Bli medlem
Bli medlem

Du är här


aap Implantate AG: aap submits CE marking application for its innovative antibacterial silver coating technology

aap Implantate AG / aap submits CE marking application for its innovative
antibacterial silvercoating technology . Processed and transmitted by NASDAQ
OMX Corporate Solutions.The issuer is solely responsible for the content of
this announcement.
Implantate AG (XETRA: AAQ.DE) announces that the design dossier for the
performance of a CE conformity assessment procedure for the antibacterial
silver coating technology developed by the company was recently submitted to
a notified body leading in the field of medical products. The conformity
assessment procedure will initially be undertaken for a silver-coated LOQTEQ®
plate. In case of a successful conformity assessment, the company plans to
extend the approval to further trauma products.

Implantate AG's silver coating technology addresses infection prevention, which is one of the critical problems in surgery that haven't yet been resolved adequately. During a procedure medical implants can become colonized by bacteria from the surrounding area forming a biofilm thereafter which can cause serious infections later. Both antibiotics and the human immune system have only a very limited effect against biofilms. It is therefore desirable to combat the biofilm formation at an early stage. This is whereaap
Implantate AG's silver coating technology becomes effective by protecting the implants' surface against bacterial colonisation. As there are no considerable resistances against silver the coating also protects against the colonisation by the particular problematic multiresistant germs.
The unique selling propositions of the silver coating technology developed byaap
Implantate AG have been demonstrated in diverse trials and consist of the high coating stability as well as the good biocompatibility and effectiveness. It is furthermore a cost-efficient coating technology due to the relatively short coating time and the comparatively low capital investment for the required coating machines.
Implantate AG's silver coating technology has a wide range of applications as a platform technology and can in a next step be used inter alia in other areas such as cardiology and dentistry or for a variety of medical instruments.
By submitting the design dossier for the performance of a CE conformity assessment procedure for the silver coating technologyaap
Implantate AG makes important progress regarding its strategic objective to accelerate value-based innovations.
Implantate AG

aap Implantate AG is a globally operating medical device company headquartered
in Berlin, Germany. The company develops, manufactures and markets trauma and
biomaterials products for orthopedics. The trauma portfolio includes besides
the innovative anatomical plating system LOQTEQ® a wide range of cannulated
screws as well as standard plates and screws. In the biomaterials business
the company is specialized on bone cements and mixing systems. In
German-speaking countriesaap
Implantate AG directly sells its trauma products to hospitals, buying
syndicates and hospital groups while it uses a broad network of distributors
in more than 60 countries at the international level. In the biomaterials
business sales are handled via OEM and private label cooperations with
several selected international orthopedic and trauma companies.aap
Implantate AG's stock is listed in the Prime Standard segment of Frankfurt
Stock Exchange (XETRA: AAQ.DE). For more information, please visit, or download the Company's investor relations app from the Apple's
App Store or Google Play.

Forward-looking statement

This release may contain forward-looking statements based on current
experience, estimates and projections of the management board and currently
available information. They are not guarantees of future performance. Various
known and unknown risks, uncertainties and other factors could lead to
material differences between the actual future results, financial situation,
development or performance of the company and the estimates given here. Many
factors could cause the actual results, performance or achievements of aap to
be materially different from those that may be expressed or implied by such
statements. These factors include those discussed inaap
's public reports. Forward-looking statements therefore speak only as of the
date they are made.aap
does not assume any obligation to update the forward-looking statements
contained in this release or to conform them to future events or

For inquiries please contact:aap
Implantate AG, Fabian Franke, Investor Relations, Lorenzweg 5, 12099 Berlin,

Tel.: +49 30 7501 9-134, fax: +49 30 7501 9-290, e-mail:


This announcement is distributed by NASDAQ OMX Corporate Solutions on behalf of NASDAQ OMX Corporate Solutions clients.
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: aap Implantate AG via Globenewswire


Författare WKR

Tala om vad ni tycker

Tala om vad ni tycker

Ni är just nu inne på en betaversion av nya aktiespararna. Lämna gärna feedback på vad ni tycker i formuläret nedan.